Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

34.91
+1.364.05%
Post-market: 34.51-0.4000-1.15%19:56 EST
Volume:1.94M
Turnover:67.25M
Market Cap:5.76B
PE:17.31
High:35.02
Open:34.38
Low:34.11
Close:33.55
52wk High:36.45
52wk Low:25.17
Shares:165.12M
Float Shares:162.42M
Volume Ratio:1.11
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.02
EPS(LYR):2.17
ROE:22.35%
ROA:9.99%
PB:3.33
PE(LYR):16.09

Loading ...

Alkermes EVP and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares

Reuters
·
Feb 03

Irish Court Sets Date to Sanction Avadel Pharmaceuticals Acquisition by Alkermes

Reuters
·
Jan 20

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)

TIPRANKS
·
Jan 16

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Avadel Shareholders Approve Acquisition by Alkermes

Reuters
·
Jan 13

Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares

Reuters
·
Jan 09

BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin

Reuters
·
Jan 06

BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge

Reuters
·
Jan 06

BUZZ-Alkermes rises as narcolepsy drug gets FDA breakthrough tag

Reuters
·
Jan 06

Alkermes Shares up 2.9% Premarket After US FDA Grants Breakthrough Therapy Designation for Its Sleep Disorder Treatment

THOMSON REUTERS
·
Jan 06

FDA Grants Breakthrough Therapy Designation to Alkermes' Alixorexton for Narcolepsy Type 1

Reuters
·
Jan 06

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

THOMSON REUTERS
·
Jan 06

Alkermes Plc - to Initiate Alixorexton Phase 3 Program in Q1 2026

THOMSON REUTERS
·
Jan 06

Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares

Reuters
·
Jan 03

Alkermes CEO to Present Corporate Overview at J.P. Morgan Healthcare Conference

Reuters
·
Dec 31, 2025

HSR Waiting Period Expires for Avadel Pharmaceuticals Acquisition by Alkermes

Reuters
·
Dec 10, 2025

Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares

Reuters
·
Dec 06, 2025

Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares

Reuters
·
Dec 02, 2025

Avadel Pharmaceuticals Plc - Scheme Meeting and Egm Scheduled for January 12, 2026

THOMSON REUTERS
·
Dec 02, 2025

A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook

Simply Wall St.
·
Dec 01, 2025